ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+ T cells by plasmacytoid dendritic cells

OncoImmunology

Volumn 2, Issue 3, 2013, Pages

  Faget, Julien ^a   Sisirak, Vanja ^b   Blay, Jean Yves ^c   Caux, Christophe ^c   Bendriss Vermare, Nathalie ^d   Ménétrier Caux, Christine ^e  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^d LabEx DEVweCAN   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

Breast cancer; ICOS; Immunosuppression; Plasmacytoid dendritic cells; Regulatory T cells

Indexed keywords

INDUCIBLE T CELL COSTIMULATOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CELL CONTACT; CELL EXPANSION; CELL INTERACTION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DISEASE ASSOCIATION; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; LYMPHOCYTIC INFILTRATION; MOLECULAR DYNAMICS; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL;

EID: 84886944581     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23185     Document Type: Article

References (10)

1. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al.Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients.Proc Natl Acad Sci U S A 2008; 105:3005-10; PMID:18287062; http://dx.doi.org/10.1073/pnas.0712237105.
2. Ribas A. Tumor immunotherapy directed at PD-1.N Engl J Med 2012; 366:2517-9; PMID:22658126; http://dx.doi.org/10.1056/NEJMe1205943.
3. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al.Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69:2000-9; PMID:19244125; http://dx.doi.org/10.1158/0008-5472.CAN-08-2360.
4. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al.Dendritic cell infiltration and prognosis of early stage breast cancer.Clin Cancer Res 2004; 10:7466-74; PMID:15569976; http://dx.doi.org/10.1158/1078-0432.CCR-04-0684.
5. Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, et al.Impaired IFN-a production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012; 72:5188-97; PMID:22836755; http://dx.doi.org/10.1158/0008-5472.CAN-11-3468.
6. Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, et al.ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells. Cancer Res 2012; 72:6130-41; PMID:23026134; http://dx.doi.org/10.1158/0008-5472.CAN-12-2409.
7. Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, et al.Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res 2012; 72:5240-9; PMID:22850422; http://dx.doi.org/10.1158/0008-5472.CAN-12-2271.
8. Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L, et al.Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery.Immunity 2008; 28:870-80; PMID:18513999; http://dx.doi.org/10.1016/j.immuni.2008.03.018.
9. Chen Y, Shen S, Gorentla BK, Gao J, Zhong XP. Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression.J Immunol 2012; 188:1698-707; PMID:22231701; http://dx.doi.org/10.4049/jimmunol.1102448.
10. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011; 71:5445-54; PMID:21708958; http://dx.doi.org/10.1158/0008-5472.CAN-11-1138.